Régis Bataille

Q: What Schools Are Affiliated With Régis Bataille

Régis Bataille is affiliated with the following schools: University of Parma, University of Nantes

Régis Bataille's AcademicInfluence.com Rankings

Régis Bataille

Medical

#2443

World Rank

#2869

Historical Rank

Hematology

#32

World Rank

#37

Historical Rank

Oncology

#147

World Rank

#153

Historical Rank

medical Degrees

Régis Bataille

Philosophy

#7084

World Rank

#10243

Historical Rank

Logic

#4159

World Rank

#5417

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Régis Bataille's Degrees

Doctorate Medicine Université Paris Cité
PhD Hematology Université Paris Cité

Why Is Régis Bataille Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Régis Bataille's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma (1996) (2706)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
Single versus double autologous stem-cell transplantation for multiple myeloma. (2003) (1015)
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. (1996) (932)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. (2007) (879)
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. (1989) (838)
Interleukin-6 in human multiple myeloma. (1995) (568)
Genetics and Cytogenetics of Multiple Myeloma (2004) (566)
Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. (1989) (489)
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. (2001) (441)
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. (2002) (417)
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. (2008) (355)
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. (1994) (338)
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. (2002) (338)
Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. (2001) (319)
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. (2002) (314)
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival (2005) (311)
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. (1992) (310)
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. (1994) (306)
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. (1989) (282)
IL‐6 up‐regulates Mcl‐1 in human myeloma cells through JAK / STAT rather than Ras / MAP kinase pathway (1999) (277)
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. (2002) (276)
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. (1995) (270)
Solitary myeloma: Clinical and prognostic features of a review of 114 cases (1981) (258)
Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. (2010) (258)
Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. (1991) (257)
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. (2006) (246)
Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130 (1994) (240)
Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. (1994) (238)
Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. (1989) (237)
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. (2007) (231)
Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients (1998) (222)
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. (1999) (222)
Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy (1993) (210)
Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. (1997) (199)
Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL‐6 and MMP‐1 by the Tumoral Environment (1999) (198)
Interleukin-6 is a growth factor for nonmalignant human plasmablasts. (2001) (197)
Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. (1999) (194)
Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. (1999) (194)
Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. (1999) (191)
High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis (2001) (187)
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. (2006) (184)
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma (1998) (180)
Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. (1983) (176)
Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. (1984) (175)
Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells (1999) (172)
Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. (1990) (172)
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. (2003) (169)
Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors (2006) (169)
C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. (1992) (163)
p53 and RAS gene mutations in multiple myeloma. (1992) (162)
Cytokine network in human multiple myeloma. (1992) (158)
Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. (2003) (151)
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report (2004) (149)
Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. (1995) (149)
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines (2011) (149)
Prognostic factors and staging in multiple myeloma: a reappraisal. (1986) (146)
Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. (2003) (141)
CD38 expression and secondary 17p deletion are important  prognostic factors in chronic lymphocytic leukaemia (2002) (136)
Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. (1990) (126)
Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. (1996) (124)
The cancer germ‐line genes MAGE‐1, MAGE‐3 and PRAME are commonly expressed by human myeloma cells (2000) (124)
Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. (2003) (122)
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. (1995) (120)
Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. (1996) (118)
Toll-like receptors: lessons to learn from normal and malignant human B cells. (2008) (117)
Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the french registry on autologous transplantation in multiple myeloma (1995) (114)
ABT-737 is highly effective against molecular subgroups of multiple myeloma. (2011) (111)
Mechanisms of bone lesions in multiple myeloma. (1992) (111)
CD28, a marker associated with tumoral expansion in multiple myeloma. (1998) (110)
Mutations of the p53 gene in human myeloma cell lines. (1992) (109)
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells [see comments] (1990) (103)
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. (1995) (101)
IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. (1991) (101)
High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization (1999) (100)
High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo (1992) (100)
In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma (1991) (97)
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. (2006) (94)
The imbalance between Bim and Mcl‐1 expression controls the survival of human myeloma cells (2004) (91)
Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma (1999) (91)
Abnormal serum bone gla protein levels in multiple myeloma: Crucial role of bone formation and prognostic implications (1990) (90)
Multiple myeloma. (1997) (89)
Molecular cloning of two isoforms of a receptor for the human hematopoietic cytokine interleukin-11. (1995) (88)
Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells (2002) (87)
Interleukin‐6 dependence of advanced malignant plasma cell dyscrasias (1992) (87)
Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. (1999) (81)
Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production (1998) (80)
A combination of anti‐interleukin 6 murine monoclonal antibody with dexamethasone and high‐dose melphalan induces high complete response rates in advanced multiple myeloma (2000) (79)
Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. (1995) (77)
Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. (2004) (76)
Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex (2005) (76)
P53 deletion is not a frequent event in multiple myeloma (1999) (75)
Cytokine gene expression in human multiple myeloma (1993) (74)
Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. (2004) (73)
CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. (2005) (72)
Phenotypic characterization of the human myeloma cell growth fraction. (2005) (72)
gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL- 6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro (1993) (72)
Endogenous association of Bim BH3‐only protein with Mcl‐1, Bcl‐xL and Bcl‐2 on mitochondria in human B cells (2005) (71)
Serum bone gla‐protein in multiple myeloma (1987) (68)
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. (2006) (67)
Pathogenesis and management of bone lesions in multiple myeloma. (1997) (67)
Familial multiple myeloma: report of fifteen families (1999) (66)
New Insights in Myeloma-induced Osteolysis (2003) (64)
CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. (1996) (64)
Significant impact of survivin on myeloma cell growth (2007) (64)
Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo (1995) (63)
Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (2005) (61)
TLR3 Ligand Induces NF-κB Activation and Various Fates of Multiple Myeloma Cells Depending on IFN-α Production1 (2009) (60)
Osteoblast stimulation in multiple myeloma lacking lytic bone lesions (1990) (59)
Importance of quantitative histology of bone changes in monoclonal gammopathy. (1986) (58)
B cell malignancies presenting with unusual bone involvement and mimicking multiple myeloma. Study of nine cases. (1987) (58)
CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. (2008) (57)
14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. (2003) (57)
Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. (2000) (57)
Amplification of the 11q23 region in acute myeloid leukemia (1999) (56)
Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy (1999) (56)
Lack of CD27 in myeloma delineates different presentation and outcome (2006) (55)
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. (2012) (55)
Validation of UBE2C protein as a prognostic marker in node-positive breast cancer (2009) (55)
CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2 (1997) (54)
Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status. (1982) (54)
The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma (1992) (54)
Qualitative and quantitative analysis of human herpesviruses in chronic and acute B cell lymphocytic leukemia and in multiple myeloma (2003) (54)
Bone scintigraphy in plasma-cell myeloma. A prospective study of 70 patients. (1982) (54)
A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy (2003) (52)
Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. (1988) (52)
Advances in Biology and Therapy of Multiple Myeloma (2013) (51)
High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. (1996) (50)
G‐CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma (1996) (50)
The gp 130 family cytokines IL‐6, LIF and OSM but not IL‐11 can reverse the anti‐proliferative effect of dexamethasone on human myeloma cells (1995) (49)
Comparative genomic hybridization detects genomic abnormalities in 80% of follicular lymphomas (1997) (48)
V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. (1999) (47)
Histologic evidence of an abnormal bone remodeling in b‐cell malignancies other than multiple myeloma (1988) (46)
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. (1990) (46)
Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. (2003) (45)
The Magnitude of Akt/Phosphatidylinositol 3′-Kinase Proliferating Signaling Is Related to CD45 Expression in Human Myeloma Cells1 (2004) (45)
Rituximab in CD20 positive multiple myeloma (2007) (44)
High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells (1995) (43)
IL-21 Stimulates Human Myeloma Cell Growth through an Autocrine IGF-1 Loop (2008) (43)
Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen (2008) (43)
Osteoclasts support the survival of human plasma cells in vitro. (2008) (43)
A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45 (2009) (42)
Deletion cartography around the D13S25 locus in B cell chronic lymphocytic leukemia and accurate mapping of the involved tumor suppressor gene. (1995) (42)
Human anti‐mouse antibody response to the injection of murine monoclonal antibodies against IL‐6 (1994) (41)
Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma. (1999) (41)
Serum interleukin 10 in early stage multiple myeloma (1992) (41)
No detectable malignant B cells in the peripheral blood of patients with multiple myeloma (1989) (40)
Spontaneous secretion of tumor necrosis factor‐beta by human myeloma cell lines (1989) (39)
VH gene analysis of clonally related IgM and IgG from human lymphoplasmacytoid B-cell tumors with chronic lymphocytic leukemia features and high serum monoclonal IgG. (1998) (38)
The CD24 antigen discriminates between pre-B and B cells in human bone marrow. (1990) (38)
Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. (2004) (37)
Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. (1990) (37)
Micro‐osteoclast resorption as a characteristic feature of B‐cell malignancies other than multiple myeloma (1990) (36)
CD45neg but Not CD45pos Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE16421 (2006) (35)
Impact of XIAP protein levels on the survival of myeloma cells (2009) (35)
An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. (1995) (35)
Canonical Nuclear Factor κB Pathway Inhibition Blocks Myeloma Cell Growth and Induces Apoptosis in Strong Synergy with TRAIL (2007) (34)
The retinoblastoma susceptibility gene RB-1 in multiple myeloma. (1997) (33)
gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. (1993) (33)
Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells. (2000) (32)
Inhibiting IL-6 in human multiple myeloma. (1992) (32)
Interleukin 6 production by cardiac myxomas may explain constitutional symptoms. (1992) (31)
The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients (2012) (31)
Serum vitamin D concentration and short-term mortality among geriatric inpatients in acute care settings (2010) (30)
Management of myeloma with bisphosphonates. (1996) (30)
Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation. (2007) (30)
Production of growth factors by human myeloma cells. (1987) (29)
BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma (2010) (29)
The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma (2009) (29)
Phosphorothioate-Modified TLR9 Ligands Protect Cancer Cells against TRAIL-Induced Apoptosis1 (2009) (28)
Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma (2015) (28)
Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. (2012) (28)
Multiple myeloma international staging system: "staging" or simply "aging" system? (2013) (27)
IL-6 upregulates its own receptor on some human myeloma cell lines. (2001) (27)
Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage. (1999) (26)
Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells (2013) (26)
Large deletions 5′ to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia (2002) (24)
Therapeutic implications of myeloma staging * (1989) (23)
A highly sensitive quantitative bioassay for human interleukin-11. (1994) (22)
Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. (2007) (21)
Lack of efficacy of clarithromycin in advanced multiple myeloma (1999) (21)
Clinical evaluation of myeloma osteoclastic bone lesions: II. Induced hypocalcemia test using salmon calcitonin. (1982) (21)
Comparative genomic hybridization is a powerful tool, complementary to cytogenetics, to identify chromosomal abnormalities in childhood acute lymphoblastic leukaemia (1997) (21)
Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells. (1999) (21)
Phenotypic and functional analysis of 1,25-dihydroxyvitamin D3 receptor mediated modulation of the human myeloma cell line RPMI 8226. (1988) (21)
[Cutaneous lesions in POEMS syndrome. Apropos of 3 case reports and a review of the literature]. (1990) (21)
Rheumatoid arthritis as a bone marrow disorder. (1996) (20)
Protein kinase C δ and η isoenzymes control the shedding of the interleukin 6 receptor α in myeloma cells (2001) (20)
Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event (2018) (20)
Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse. (2004) (20)
CLONAL REARRANGEMENT OF IMMUNOGLOBULIN GENES IN THE PERIPHERAL BLOOD OF MULTIPLE MYELOMA PATIENTS (1989) (20)
Serum beta 2 microglobulin in multiple myeloma. A critical review. (1987) (19)
Letter to the editor: The bone‐resorbing activity of interleukin‐6 (1991) (19)
Plasma beta-2 microglobulin as a marker of frailty in older adults: a pilot study. (2011) (19)
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial (2009) (19)
Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma. (1987) (19)
Reactive plasmacytoses can mimick plasma cell leukemia: Therapeutical implications (2007) (18)
IgG‐secreting lymphoplasmacytoid leukaemia: a B‐cell disorder with extensively mutated VH genes undergoing Ig isotype‐switching frequently associated with trisomy 12 (2000) (18)
Complexes of α1-microglobulin and monomeric IgA in multiple myeloma and normal human sera (1985) (18)
CD130 rather than CD126 expression is associated with disease activity in multiple myeloma (1999) (18)
Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis. (1993) (18)
New insights in the clinical biology of multiple myeloma. (1997) (17)
Activating Ras mutations in patients with plasma-cell disorders: a reappraisal. (2002) (16)
Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma (2002) (16)
Molecular analysis of the IL‐6 receptor in human multiple myeloma, an IL‐6‐related disease (1994) (16)
Reactive plasmacytoses, a model for studying the biology of human plasma cell progenitors and precursors. (2000) (16)
Immunoglobulins D and M multiple myeloma variants are heavily mutated. (1997) (15)
Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products. (1997) (14)
Clinical evaluation of response or escape to chemotherapy and of survival of patients with multiple myeloma. A prospective study of 202 patients (1975-1982). (1984) (14)
In vitro osteolytic activity of human myeloma plasma cells and the clinical evaluation of myeloma osteoclastic bone lesions. (1984) (14)
Up‐regulation of interleukin (IL)‐6 receptor gene expression in vitro and in vivo in IL‐6 deprived myeloma cells (1992) (14)
Lack of benefit of CD34+ cell selected over non-selected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study (2000) (13)
Myeloma bone marrow acid phosphatase staining: a correlative study of 38 patients (1980) (13)
Myeloma bone marrow acid phosphatase staining: a correlative study of 38 patients. (1980) (13)
Human natural killer cells suppress the proliferation of B cells. (1990) (13)
Acute effects of salmon calcitonin in multiple myeloma: a valuable method for serial evaluation of osteoclastic lesions and disease activity--a prospective study of 125 patients. (1985) (13)
13q14 deletions are not primary events in B-cell chronic lymphocytic leukemia: a study of 100 patients using fluorescence in situ hybridization. (1996) (13)
High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma. (1993) (13)
Osteoclast cytomorphometry demonstrates an abnormal population in B cell malignancies but not in multiple myeloma (2007) (13)
No expansion of the pre-B and B-cell compartments in the bone marrow of patients with multiple myeloma. (1991) (12)
Multiple Myeloma as a Bone Disease? The Tissue Disruption-Induced Cell Stochasticity (TiDiS) Theory (2020) (12)
Immunomodulating IL-6 activity by murine monoclonal antibodies. (1995) (11)
Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? (1993) (11)
Production of interleukin 2 in multiple myeloma. (1986) (11)
The multiple myeloma bone eco-system and its relation to oncogenesis. (2015) (11)
Clinical applications of IL6 inhibitors. (1992) (10)
Serum beta-2-microglobulin binding activity in monoclonal gammopathy: correlative study and clinical significance. (1983) (10)
Ectopic secretion of osteocalcin, the major non‐collagenous bone protein, by the myeloma cell line NCI‐H929 (1996) (9)
Limiting dilution cloning of B cells from patients with multiple myeloma: Emergence of non‐malignant B‐cell lines (1989) (9)
Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment? (2004) (9)
Effects of an anti-interleuktn-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia (1993) (9)
Autoantibodies in D-penicillamine-induced myasthenia gravis: a comparison with idiopathic myasthenia and rheumatoid arthritis. (1991) (9)
Increased singlet oxygen-induced secondary ROS production in the serum of cancer patients. (2012) (8)
In Vitro Production of Beta2 Microglobulin by Human Myeloma Cells (1988) (8)
CD72 is constantly expressed in chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. (1994) (8)
Reactive plasmacytoses in multiple myeloma during hematopoietic recovery with G- or GM-CSF. (2000) (8)
Phosphorothioate-Modified TLR 9 Ligands Protect Cancer Cells against TRAIL-Induced Apoptosis 1 (2009) (7)
[Survivin in cancerology : molecular aspects and therapeutic applications]. (2008) (7)
[Advances in the biology of multiple myeloma]. (1990) (7)
[Immunoglobulin D multiple myeloma. A retrospective study in the Languedoc region]. (1989) (7)
The mechanisms of bone lesions in human plasmacytomas. (1995) (6)
The bone-resorbing activity of interleukin-6. (1991) (6)
Analysis of the B-cell compartment in plasma cell leukemia and multiple myeloma: immunoglobulin gene rearrangement of EBV-infected B-cell lines. (1993) (6)
In vitro production of beta 2 microglobulin by human myeloma cells. (1988) (6)
[Occurrence of multiple myeloma 5 years after renal transplantation]. (1988) (6)
Interrelationship between autoimmunity and B-lymphoid cell oncogenesis in humans. (1989) (5)
Presence of beta-2 microglobulin and alpha-2 macroglobulin in kappa AL-amyloidosis. (1992) (5)
Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma (2005) (5)
Serum beta-2-microglobulin (beta 2m) in myeloma: toward a simple prognostic stratification using beta 2M and acute-phase proteins? [letter; comment] (1991) (5)
Antibody specificity of the human monoclonal immunoglobulins: the elusive target antigen. (1989) (5)
Role of interleukin-6 in multiple myeloma. (1992) (5)
[Role of the assay of serum beta 2 microglobulin in the clinical evaluation of myeloma]. (1986) (4)
CD5 positive B lymphocytes: a link between autoimmunity and B-cell oncogenesis. (1988) (4)
The relationship between autoimmune states and B cell proliferations. (1989) (4)
[Synovial amyloidosis disclosing myeloma. Clinical, arthroscopic and immunochemical aspects]. (1988) (4)
Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q‐ syndrome (2000) (4)
Validation of 213Bi-o~ Radioimmunotherapy for Multiple Myeloma I (1999) (4)
Immunofixation improves the detection of monoclonal gammopathy of undetermined significance (M.G.U.S.) in patients with rheumatoid arthritis. (1987) (4)
[Apparently isolated plasmacytoma of bone. Clinical and prognostic data. 114 cases and review of literature (author's transl)]. (1981) (4)
A subset of mantle cell lymphoma exhibits stable disease and correlates with mutated VH genes and low CD38 expression (2001) (4)
The Critical Role of Survivin in the Survival and Proliferation of Human Myeloma Cells. (2005) (4)
Serum levels of beta 2 microglobulin and interleukin-6 to differentiate monoclonal gammopathy of undetermined significance [letter; comment] (1992) (3)
Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma (2006) (3)
[Contribution of bone biopsy with histomorphometry in the evaluation of monoclonal gammopathy]. (1987) (3)
Alternating combination of alkylating agents and vincristine, doxorubicin, and dexamethasone in multiple myeloma. (1991) (3)
[Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years]. (1980) (3)
Polyclonal immunoglobulins in malignant plasma cell dyscrasias. (1984) (3)
Serum levels of beta 2 microglobulin and interleukin-6 to differentiate monoclonal gammopathy of undetermined significance. (1992) (3)
CD45 but Not CD45 Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642 (2006) (3)
[Multiple myeloma of bones. Retrospective study of prognostic factors based on a series of 243 patients]. (1979) (3)
The defect in peripheral blood B-cell activation in patients with multiple myeloma is not due to a deficiency in the production of B-cell growth and differentiation factors (2004) (3)
IL-6 is a growth factor for nonmalignant human plasmablasts (2001) (3)
The Pan-Bcl-2 Inhibitor GX15-O70 Induces Apoptosis in Human Myeloma Cells by Noxa Induction and Strongly Enhances Melphalan, Bortezomib or TRAIL-R1 Antibody Apoptotic Effect. (2006) (3)
No preferential use of the VH(V) family in human multiple myeloma (1989) (2)
Interferons in the treatment of multiple myeloma. (1990) (2)
Characterization of polyclonal autoantibodies specific for beta 2-microglobulin in multiple myeloma sera. (1983) (2)
Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group. (2006) (2)
REGRESSION OF EXCESSIVE BONE REMODELLING BY INTERFERON ALPHA‐2‐A IN A PATIENT WITH HAIRY CELL LEUKEMIA: To the Editor: (1988) (2)
Survivin Expression, Regulation and Biological Role in Multiple Myeloma. (2004) (2)
Complexes of alpha 1-microglobulin and monomeric IgA in multiple myeloma and normal human sera. (1985) (2)
Mcl-1 Sequesters Pro-Apoptotic BH3-Only Bim To Inhibit Its Collaboration with Bax in Myeloma Cells. (2004) (2)
[Prolonged survival in multiple myeloma. Characteristics of presentation and response to treatment of 73 patients who survived 5 years or longer]. (1986) (2)
CD45 Expression in Human Myeloma Cells -Kinase Proliferating Signaling Is Related to ¢ The Magnitude of Akt/Phosphatidylinositol 3 (2004) (2)
[Arthropathy of the shoulder caused by bismuth poisoning]. (1978) (2)
Recent advantages in the biology of IL-6 in multiple myeloma (1991) (2)
Unusual B-cell cancers that produce bone-resorbing factors and can mimic multiple myeloma. (1985) (2)
Serum beta-2-microglobulin (beta 2m) in myeloma: toward a simple prognostic stratification using beta 2M and acute-phase proteins? (1991) (2)
Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6/RUNX1-rearranged childhood acute lymphoblastic leukemia (2007) (1)
Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells. (2005) (1)
Delay and not deficiency in cap formation of peripheral blood B cells in patients with multiple myeloma (1988) (1)
[IgM kappa Waldenström's disease with cryoglobulinemia disclosed by visceral leishmaniasis]. (1988) (1)
[Refractory anemia with partial myeloblastosis in multiple myeloma treated with melphalan]. (1977) (1)
Signaling by a Murine Anti-IGF-1 R Cells Are Sensitive to the Inhibition of IGF-1 Human Myelomapos but Not CD 45 negCD 45 and (2006) (1)
Human tumor stem cells, the petri dish and the patient. A tribute to Sydney E. Salmon. (2011) (1)
[Cytokines and lymphoplasmocytic proliferations: essential role of interleukin 6]. (1993) (1)
[Growth factors in multiple myeloma]. (1990) (1)
The Coexpression of CD11a and CD45bright Is the Hallmark of Proliferating Myeloma Cells. (2004) (1)
myeloma cells apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated (2011) (1)
Major immunoglobulin capping deficiency in the peripheral blood B cells of patients with Sjögren's syndrome. (1992) (1)
[Role of glucocorticoids in the treatment of multiple myeloma]. (1996) (1)
[Diffuse interstitial fibrosis manifesting polymyositis]. (1983) (1)
TP53 Positively Regulates Cell Death through TRAILR2 (DR5) but Negatively through TRAILR1 (DR4) In Myeloma Cells (2010) (1)
Conserved natural humoral immunity to thyroglobulin in patients with multiple myeloma (1992) (0)
Etiology of Paget's disease of bone: A new perspective (1992) (0)
[Serum beta-2-microglobulin in multiple myeloma. Practical value]. (1981) (0)
[Rheumatismal manifestations of coloenteropathies]. (1976) (0)
Osteoclasts but Not Macrophages or Dendritic Cells Support Long-Term Plasma Cell Survival. (2006) (0)
TRAILR Triggering by Human Antibodies Induces Apoptosis through an Early Cleavage of Mcl-1 and Caspase 3 in Myeloma Cells. (2005) (0)
A Humanized Anti-IGF-1R Monoclonal Antibody (AVE1642) Synergizes with Bortezomib To Induce Apoptosis in CD45neg Myeloma Cells. (2006) (0)
comparative study with normal plasma cells Expression of CD28 and CD40 in human myeloma cells: a (2011) (0)
B310 Molecular Classification of Myeloma Cell Lines Is Related to that of Patients with Myeloma (2009) (0)
Selection of fully human anti-CD138 for detecting and therapy of multiple myeloma from combinatorial libraries and generation of novel anti-myeloma antibodies (2005) (0)
Metalloproteinase-2 Activation Its Potential Involvement in ( Matrilysin ) by Human Myeloma Cells and Production of Metalloproteinase-7 (1999) (0)
MMP-1 by Myeloma Cells Metalloproteinase-9 ( MMP-9 ) , Activation of proMMP-2 , and Induction of Metalloproteinases in Multiple Myeloma : Production of Matrix (1997) (0)
[Autologous peripheral blood selected CD34+ cell transplantation in the treatment of multiple myeloma]. (2001) (0)
[Simultaneous myeloma in husband and wife. Description and review of the literature]. (1987) (0)
[Multiple myeloma: diagnosis and prognosis]. (1990) (0)
[Solitary plasmocytoma of bone. Apropos of 25 cases]. (1978) (0)
[An attempt at identification of osteoclastic activation factors implicated in myeloma]. (1988) (0)
IgG-Secreting B-Cell Lymphoplasmocytoid Leukaemia : Molecular Characterization of Igh Rearrangements. (2008) (0)
angiogenesis angiopoietin-1 and its potential relationship to myeloma-induced Proangiogenic properties of human myeloma cells: production of (2013) (0)
Growth through an Autocrine IGF-1 Loop IL-21 Stimulates Human Myeloma Cell (2008) (0)
Unsupervised Analysis of Gene Expression Profile of 37 Human Myeloma Cell Lines Identifies 5 Classes of HMCL Characterized by a Set of 213 Genes Related to Molecular Classification of Patients with Multiple Myeloma (2008) (0)
PLASMA CELL LABELING INDEX, BETA 2-MICROGLOBULIN, AND C-REACTIVE PROTEIN :WHATH IS THE BEST COMBINATION FOR MYELOME PROGNOSIS ? AUTHORS' RESPONSE (1993) (0)
Identification and Hierarchy of Clonogenic Factors for Human Myeloma Cells: IL-6 for CD45+ Versus IL-6 and Growth Factors for CD45-. (2005) (0)
Le syndrome POEMS: à propos d'un cas (1988) (0)
[Lysis of the odontoid process in rheumatoid polyarthritis]. (1978) (0)
[Efficacy and tolerance of methotrexate in rheumatoid polyarthritis. Results of an open study on 104 patients]. (1989) (0)
[Human plasmacytoma from biology to clinical practice]. (1993) (0)
induction of an oncostatin M autocrine loop Interleukin-10 is a growth factor for human myeloma cells (2002) (0)
[Associated and secondary chondrocalcinosis]. (1977) (0)
hematopoietic cytokine interleukin-11 Molecular cloning of two isoforms of a receptor for the human (2011) (0)
[Solid tumors which induce autoimmune conditions]. (1988) (0)
Synovial membrane metaplasia to secondary lymphoid organs: role in the pathogenesis of auto-immune arthritis. (1999) (0)
Supplementary Table 1 and Supplementary Figure 1 and 2 (2009) (0)
Phenotype and Cytokines Production by Human Myeloma Cell Lines (1988) (0)
The Complex Mcl-1/Bim Regulates the Sensitivity of Human Myeloma Cells to Melphalan. (2005) (0)
[Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)]. (1979) (0)
Myeloma Cell Self-Renewal Depends on JAG2 Expression and Is Mediated by IGF1 or SCF Loop (2010) (0)
multiple myeloma: a reappraisal 18 years after (letter) Human myeloma cell lines as a tool for studying the biology of (2011) (0)
Phenotypic and Functional Analysis of 1 , 25-Dihydroxyvitamin D 3 Receptor Mediated Modulation of the Human Myeloma Cell Line RPM ! 822 Q (2006) (0)
B148 Role of Bcl-2/Bik Complex in Myeloma Cell Apoptosis (2009) (0)
Deletions Are Not Primary Events in B-Cell Chronic Lymphocytic Leukemia : A Study of 100 Patients Using Fluorescence in Situ Hybridization 1 (2005) (0)
reappraisal Activating Ras mutations in patients with plasma-cell disorders: a (2011) (0)
of the Intergroupe Francophone du Myélome Genetic abnormalities and survival in multiple myeloma: the experience (2011) (0)
[Chemotherapy of multiple bone myeloma. Prognostic features and response criteria (First part) (author's transl)]. (1979) (0)
[Effect of the manner of the response to chemotherapy on the prognosis of myeloma. Preliminary study]. (1981) (0)
Synergistic Antitumor Effects of alpha-Radioimmunotherapy and Paclitaxel or Doxorubicin on Human Myeoloma Cells. (2005) (0)
[Immunology of myeloma]. (1987) (0)
The international St-aging system as a prognostic marker in general senior population: Findings from the EPIDOS cohort study. (2019) (0)
myeloma ABT-737 is highly effective against molecular subgroups of multiple (2011) (0)
High Bcl-2/Mcl-1 Gene Expression Ratio Identifies Molecular Sub-Groups of Multiple Myeloma Patients Extremely Sensitive to ABT-737 (2010) (0)
HLA-Cw6 Alloreactive CTL Recognizing HLA-CW6+ Myeloma Cells but Not Non-Myeloma HLA-Cw6+ Cells Are Peptide Dependent. (2004) (0)
[Evaluation of the tumor mass and its regression under treatment of multiple myeloma of the bones. Critical comments apropos of 22 patients]. (1978) (0)
elderly multiple myeloma patients ineligible for high-dose therapy Dexamethasone-based regimens versus melphalan-prednisone for (2011) (0)
[Treatment of malignant hypercalcemia with salmon calcitonin given in intravenous perfusion]. (1977) (0)
Pathogenesis and management of bone lesions in multiple myeloma : Multiple myeloma (1997) (0)
Abstract B16: The pro-apoptotic effect of dexamethasone mediated by GILZ and Bim up-regulation is related to genetic heterogeneity of multiple myeloma. (2015) (0)
[Myelomatous bone involvement in the man]. (1993) (0)
[Association of papular mucinosis and IgG lambda multiple myeloma]. (1978) (0)
Tumoral Sample Peripheral blood Pleural effusion Peripheral blood Pleural effusion Peripheral blood Peripheral blood Peripheral blood Peripheral blood Peripheral blood Bone marrow and the percentages of myeloma cells (2002) (0)
Autoimmune conditions induced by epithelial solid tumors (2004) (0)
Secondary ROS or peroxides after singlet oxygen production (2011) (0)
[Are measurements of the urinary excretion of fasting calcium, phosphorus and hydroxyproline usefull in myeloma?]. (1985) (0)
Interleukin-l0 Is a Proliferation Factor But Not a Differentiation Factor for Human Myeloma Cells (2002) (0)
[Prostatic osteosis. Retrospective study of 110 cases treated with high-dose estrogens]. (1979) (0)
powerful myeloma staging system C-reactive protein and beta-2 microglobulin produce a simple and (2013) (0)
Agonist Anti-TRAILR1 Human Mab, Hgs-ETR1, Induces Myeloma Cell Death Mainly through the Intrinsic Pathway of Apoptosis. (2008) (0)
Abstract C28: Dexamethasone-induced apoptosis in multiple myeloma cells is restricted to t(14;16) and t(4;14) molecular subgroups due to a combined down-regulation of MAF and an up-regulation of Bim. (2013) (0)
Interleukine 6 production may explain constitutional symptoms of cardiac myxomas (1990) (0)
A bone paradigm challenging the standard model of myeloma oncogenesis. (2022) (0)
B104 IL-21 Induces Myeloma Cell Growth Via IGF-1 Autocrine Loop (2009) (0)
[Is there any real progress in the chemotherapy of multiple myeloma?]. (1985) (0)
Myeloma and osteoclast relationship (2015) (0)
Molecular Prognosis in Multiple Myeloma: The IFM Experience. (2006) (0)
Establishment of a predictive classifier of node-positive breast cancer patients treated by FEC100 chemotherapy using gene expression profiling. (2016) (0)
[Multiple myeloma: anatomic documents]. (1979) (0)
Mcl-1 Is Overexpressed in Multiple Myeloma and Correlates with Disease Severity. (2004) (0)
receiving high-dose therapy 2-microglobulin produce a powerful myeloma staging system for patients β Chromosome 13 abnormalities identified by FISH analysis and serum (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Régis Bataille?

Régis Bataille is affiliated with the following schools:

Régis Bataille's Academic­Influence.com Rankings

Régis Bataille's Degrees

Why Is Régis Bataille Influential?

Régis Bataille's Published Works

Published Works

What Schools Are Affiliated With Régis Bataille?

Régis Bataille's AcademicInfluence.com Rankings